Figure 1.
Overall survival of relapsed/refractory patients with B-acute lymphoblastic leukemia after treatment with inotuzumab ozogamicin. Green and red dotted lines indicate upper and lower 95% confidence interval.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.